AKT1 and melanoma: Preclinical studies performed in human melanoma cell lines have highlighted that co-targeting of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways with Raf and Akt/mTOR inhibitors resulted in synergistic inhibition [297].